ArticleBMJ open respiratory research2025
Inhaler use and their carbon footprint in Germany: a 10-year analysis (2013-2022).
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInhalers are essential for managing asthma and chronic obstructive pulmonary disease; however, their environmental effects vary significantly. Pressurised metered-dose inhalers (pMDIs) contain potent greenhouse gases (GHGs), resulting in a much higher carbon footprint (CF) than non-propellant inhalers (NPIs). Consequently, reducing the use of pMDIs is seen as an important contribution to reduce the healthcare sector's effect on climate change. This study analyses inhaler dispensing trends in Germany, estimates their resulting CF and quantifies the potential GHG savings from increased NPI use.
methodsDispensing data at the expense of statutory health insurances, covering nearly 90% of the German population, were analysed from 2013 to 2022 across three age groups. Annual dispensing shares and CF estimates based on life cycle assessment-derived CF values were calculated for four inhaler types: pMDIs with hydrofluorocarbon (HFC)-134a, pMDIs with HFC-227ea, dry powder inhalers (DPIs), and soft mist inhalers (SMIs). Two scenario calculations estimated the potential GHG savings.
resultsBetween 2013 and 2022, the total number of dispensed defined daily doses of inhalers increased by 14%, with no significant shift towards lower-emission inhalers (2013, 55% NPIs; 2022, 52% NPIs). Consequently, the total CF increased from 459 kilotonnes of carbon dioxide equivalent (kt CO
conclusionDespite climate neutrality goals, inhaler-related CF has continued to rise because of stable pMDI usage rates. The substantial potential for GHG reduction highlights the necessity and feasibility of a sustainable change in clinical prescription practice. Our insights could support the promotion of climate-friendly inhalers across other European countries with similar prescription patterns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.